496 results on '"Fukami, Kei"'
Search Results
152. Involvement of advanced glycation end product-induced asymmetric dimethylarginine generation in endothelial dysfunction
153. Evidence for a Positive Association Between Serum Carnitine and Free Testosterone Levels in Uremic Men with Hemodialysis
154. Corrigendum to “PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation” [Microvasc. Res. 85 (1) (2013) 54–58]
155. Effects of Switching From Calcium Carbonate to Lanthanum Carbonate on Bone Mineral Metabolism in Hemodialysis Patients
156. A case of toxic epidermal necrolysis induced by losartan and furosemide in patient with chronic renal failure: case report
157. PEDF inhibits AGE-induced podocyte apoptosis via PPAR-gamma activation
158. Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients
159. Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice
160. Role of advanced glycation end products (AGEs) and oxidative stress in vascular complications in diabetes
161. A New Vasculitis Activity Score for Predicting Death in Myeloperoxidase-Antineutrophil Cytoplasmic Antibody-Associated Vasculitis Patients
162. Beneficial Cardiometabolic Actions of Telmisartan Plus Amlodipine Therapy in Elderly Patients With Poorly Controlled Hypertension
163. A hemodialysis patient who developed aortic graft infection, infected aneurysm and aortoesophageal fistula due to vascular access infection: An autopsy report
164. A Case of Acute Kidney Injury due to Intravenous Zoledronic Acid Hydrate, Improved with Bortezomib Plus Dexamethazone Therapy in a Patient with Multiple Myeloma.
165. Association of Asymmetric Dimethylarginine with Severity of Kidney Injury and Decline in Kidney Function in IgA Nephropathy
166. Nifedipine inhibits advanced glycation end products (AGEs) and their receptor (RAGE) interaction-mediated proximal tubular cell injury via peroxisome proliferator-activated receptor-gamma activation
167. Efficacy of Combination Therapy with Telmisartan Plus Amlodipine in Patients with Poorly Controlled Hypertension
168. Irbesartan Inhibits Albumin-Elicited Proximal Tubular Cell Apoptosis and Injury In Vitro
169. Protective role of pigment epithelium‐derived factor (PEDF) in early phase of experimental diabetic retinopathy
170. Nifedipine, a calcium channel blocker, inhibits advanced glycation end product (AGE)-elicited mesangial cell damage by suppressing AGE receptor (RAGE) expression via peroxisome proliferator-activated receptor-gamma activation
171. RAGE-Induced Cytosolic ROS Promote Mitochondrial Superoxide Generation in Diabetes
172. Clinical Utility of Acarbose, an α-Glucosidase Inhibitor in Cardiometabolic Disorders
173. Circulating Matrix Metalloproteinase-2 Is an Independent Correlate of Proteinuria in Patients with Chronic Kidney Disease
174. Agents that block advanced glycation end product (AGE)-RAGE (receptor for AGEs)-oxidative stress system: a novel therapeutic strategy for diabetic vascular complications
175. Role of AGEs in Diabetic Nephropathy
176. Olmesartan blocks advanced glycation end products (AGEs)-induced angiogenesis in vitro by suppressing receptor for AGEs (RAGE) expression
177. Dimethylarginine Dimethylaminohydrolase Prevents Progression of Renal Dysfunction by Inhibiting Loss of Peritubular Capillaries and Tubulointerstitial Fibrosis in a Rat Model of Chronic Kidney Disease
178. Polymorphonuclear Leukocytes May Impair Endothelial Function
179. Agents in development for the treatment of diabetic nephropathy
180. Comparison of Histological Findings and Parathyroid Scintigraphy in Hemodialysis Patients with Secondary Hyperparathyroid Glands
181. Iron as a Novel Risk Factor for Endothelial Dysfunction in Humans
182. Endothelial Dysfunction and Subclincal Atherosclerosis in Insulin Resistance Syndrome
183. Reduction of Homocyst (e) Ine to Subnormal Levels Restores Endothelial Function in Normohomocyst (E) Inemic Habitual Smokers: Effect of Folic Acid Supplementation
184. Minimal change nephrotic syndrome associated with rifampicin treatment
185. Effects of switching from oral administration to intravenous injection of l-carnitine on lipid metabolism in hemodialysis patients.
186. Dialysate Vascular Endothelial Growth Factor Is an Independent Determinant of Serum Albumin Levels and Predicts Future Withdrawal From Peritoneal Dialysis in Uremic Patients.
187. Serum asymmetric dimethylarginine levels are independently associated with procollagen III N-terminal peptide in nonalcoholic fatty liver disease patients.
188. Potential Inhibitory Effects of l-Carnitine Supplementation on Tissue Advanced Glycation End Products in Patients with Hemodialysis.
189. Dipeptidyl peptidase-4 deficiency protects against experimental diabetic nephropathy partly by blocking the advanced glycation end products-receptor axis.
190. Oral L-Carnitine Supplementation Increases Trimethylamine-N-oxide but Reduces Markers of Vascular Injury in Hemodialysis Patients
191. DNA aptamer raised against AGEs blocks the progression of experimental diabetic nephropathy.
192. Experimental diabetic nephropathy is accelerated in matrix metalloproteinase-2 knockout mice.
193. Decreased serum carnitine is independently correlated with increased tissue accumulation levels of advanced glycation end products in haemodialysis patients.
194. Tissue level of advanced glycation end products is an independent determinant of high-sensitivity C-reactive protein levels in haemodialysis patients.
195. Association of asymmetric dimethylarginine with severity of kidney injury and decline in kidney function in IgA nephropathy.
196. Interstitial Foxp3-positive T cells may predict renal survival in patients with myeroperoxidase anti-neutrophil cytoplasmic antibody-associated glomerulonephritis.
197. Accurate estimation of protein/creatinine ratio on urine sample in CKD patients.
198. Positive association of serum levels of advanced glycation end products and high mobility group box–1 with asymmetric dimethylarginine in nondiabetic chronic kidney disease patients.
199. IL-1RI deficiency ameliorates early experimental renal interstitial fibrosis.
200. Circulating Matrix Metalloproteinase-2 Is an Independent Correlate of Proteinuria in Patients with Chronic Kidney Disease.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.